Compare LYRA & INBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LYRA | INBS |
|---|---|---|
| Founded | 2005 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4M | 5.3M |
| IPO Year | 2020 | N/A |
| Metric | LYRA | INBS |
|---|---|---|
| Price | $3.47 | $4.85 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $16.00 | N/A |
| AVG Volume (30 Days) | 35.1K | ★ 43.8K |
| Earning Date | 11-12-2025 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $600,000.00 | ★ $3,292,042.00 |
| Revenue This Year | N/A | $778.48 |
| Revenue Next Year | $93.90 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 3.26 |
| 52 Week Low | $2.84 | $4.55 |
| 52 Week High | $37.50 | $27.50 |
| Indicator | LYRA | INBS |
|---|---|---|
| Relative Strength Index (RSI) | 40.20 | 68.78 |
| Support Level | $3.51 | $0.54 |
| Resistance Level | $4.04 | $7.25 |
| Average True Range (ATR) | 0.33 | 0.49 |
| MACD | 0.03 | 0.31 |
| Stochastic Oscillator | 39.62 | 65.54 |
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.
Intelligent Bio Solutions Inc is a life sciences company developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. Its Biosensor Platform is developing and launching diagnostic tests urgently needed to help people living with chronic diseases. It also engages in the advancement of portable drug abuse testing through the analysis of fingerprint sweat. The test is non-invasive, hygienic, and fast, and screens for recent use of opioids, cocaine, methamphetamines, benzodiazepines, and marijuana. The company operates through new reportable segments: United Kingdom; Asia Pacific (APAC); Americas; and Rest of World, of which United Kingdom derives maximum revenue.